vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Paymentus Holdings, Inc. (PAY). Click either name above to swap in a different company.
Paymentus Holdings, Inc. is the larger business by last-quarter revenue ($330.5M vs $247.1M, roughly 1.3× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 6.3%, a 4.9% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 28.1%). Paymentus Holdings, Inc. produced more free cash flow last quarter ($45.0M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 33.7%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Paymentus Holdings, Inc. is a leading cloud-based bill payment and customer engagement technology provider. It offers integrated digital payment solutions, billing automation tools, and self-service portals for enterprises across utilities, financial services, government, healthcare, and telecommunications segments, primarily operating in the North American market.
ANIP vs PAY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $330.5M |
| Net Profit | $27.5M | $20.7M |
| Gross Margin | — | 25.4% |
| Operating Margin | 14.1% | 7.3% |
| Net Margin | 11.1% | 6.3% |
| Revenue YoY | 29.6% | 28.1% |
| Net Profit YoY | 367.5% | 57.2% |
| EPS (diluted) | $1.14 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $330.5M | ||
| Q3 25 | $227.8M | $310.7M | ||
| Q2 25 | $211.4M | $280.1M | ||
| Q1 25 | $197.1M | $275.2M | ||
| Q4 24 | $190.6M | $257.9M | ||
| Q3 24 | $148.3M | $231.6M | ||
| Q2 24 | $138.0M | $197.4M | ||
| Q1 24 | $137.4M | $184.9M |
| Q4 25 | $27.5M | $20.7M | ||
| Q3 25 | $26.6M | $17.7M | ||
| Q2 25 | $8.5M | $14.7M | ||
| Q1 25 | $15.7M | $13.8M | ||
| Q4 24 | $-10.3M | $13.1M | ||
| Q3 24 | $-24.2M | $14.4M | ||
| Q2 24 | $-2.3M | $9.4M | ||
| Q1 24 | $18.2M | $7.2M |
| Q4 25 | — | 25.4% | ||
| Q3 25 | — | 24.1% | ||
| Q2 25 | — | 25.5% | ||
| Q1 25 | — | 24.0% | ||
| Q4 24 | — | 25.6% | ||
| Q3 24 | — | 26.2% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | 28.5% |
| Q4 25 | 14.1% | 7.3% | ||
| Q3 25 | 15.9% | 6.4% | ||
| Q2 25 | 6.6% | 5.7% | ||
| Q1 25 | 13.3% | 5.7% | ||
| Q4 24 | -2.3% | 5.5% | ||
| Q3 24 | -13.8% | 5.2% | ||
| Q2 24 | 3.7% | 5.2% | ||
| Q1 24 | 14.8% | 4.5% |
| Q4 25 | 11.1% | 6.3% | ||
| Q3 25 | 11.7% | 5.7% | ||
| Q2 25 | 4.0% | 5.3% | ||
| Q1 25 | 8.0% | 5.0% | ||
| Q4 24 | -5.4% | 5.1% | ||
| Q3 24 | -16.3% | 6.2% | ||
| Q2 24 | -1.7% | 4.7% | ||
| Q1 24 | 13.2% | 3.9% |
| Q4 25 | $1.14 | $0.16 | ||
| Q3 25 | $1.13 | $0.14 | ||
| Q2 25 | $0.36 | $0.11 | ||
| Q1 25 | $0.69 | $0.11 | ||
| Q4 24 | $-0.45 | $0.11 | ||
| Q3 24 | $-1.27 | $0.11 | ||
| Q2 24 | $-0.14 | $0.07 | ||
| Q1 24 | $0.82 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $320.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $560.4M |
| Total Assets | $1.4B | $667.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $320.9M | ||
| Q3 25 | $262.6M | $287.9M | ||
| Q2 25 | $217.8M | $266.4M | ||
| Q1 25 | $149.8M | $245.8M | ||
| Q4 24 | $144.9M | $205.9M | ||
| Q3 24 | $145.0M | $187.5M | ||
| Q2 24 | $240.1M | $188.8M | ||
| Q1 24 | $228.6M | $180.1M |
| Q4 25 | $540.7M | $560.4M | ||
| Q3 25 | $505.8M | $537.4M | ||
| Q2 25 | $436.8M | $516.7M | ||
| Q1 25 | $418.6M | $500.4M | ||
| Q4 24 | $403.7M | $485.6M | ||
| Q3 24 | $405.9M | $468.8M | ||
| Q2 24 | $455.8M | $451.6M | ||
| Q1 24 | $452.0M | $439.4M |
| Q4 25 | $1.4B | $667.9M | ||
| Q3 25 | $1.4B | $644.4M | ||
| Q2 25 | $1.3B | $609.5M | ||
| Q1 25 | $1.3B | $590.9M | ||
| Q4 24 | $1.3B | $576.2M | ||
| Q3 24 | $1.3B | $552.9M | ||
| Q2 24 | $920.8M | $527.7M | ||
| Q1 24 | $914.5M | $514.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $45.1M |
| Free Cash FlowOCF − Capex | $29.1M | $45.0M |
| FCF MarginFCF / Revenue | 11.8% | 13.6% |
| Capex IntensityCapex / Revenue | 0.5% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.10× | 2.18× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $161.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $45.1M | ||
| Q3 25 | $44.1M | $35.1M | ||
| Q2 25 | $75.8M | $31.5M | ||
| Q1 25 | $35.0M | $50.4M | ||
| Q4 24 | $15.9M | $27.9M | ||
| Q3 24 | $12.5M | $6.7M | ||
| Q2 24 | $17.4M | $18.0M | ||
| Q1 24 | $18.3M | $11.0M |
| Q4 25 | $29.1M | $45.0M | ||
| Q3 25 | $38.0M | $35.0M | ||
| Q2 25 | $71.8M | $31.4M | ||
| Q1 25 | $32.5M | $50.4M | ||
| Q4 24 | $13.5M | $27.8M | ||
| Q3 24 | $7.7M | $6.7M | ||
| Q2 24 | $13.0M | $17.8M | ||
| Q1 24 | $13.7M | $10.8M |
| Q4 25 | 11.8% | 13.6% | ||
| Q3 25 | 16.7% | 11.3% | ||
| Q2 25 | 34.0% | 11.2% | ||
| Q1 25 | 16.5% | 18.3% | ||
| Q4 24 | 7.1% | 10.8% | ||
| Q3 24 | 5.2% | 2.9% | ||
| Q2 24 | 9.4% | 9.0% | ||
| Q1 24 | 10.0% | 5.9% |
| Q4 25 | 0.5% | 0.0% | ||
| Q3 25 | 2.7% | 0.0% | ||
| Q2 25 | 1.9% | 0.0% | ||
| Q1 25 | 1.3% | 0.0% | ||
| Q4 24 | 1.3% | 0.0% | ||
| Q3 24 | 3.2% | 0.0% | ||
| Q2 24 | 3.2% | 0.1% | ||
| Q1 24 | 3.3% | 0.1% |
| Q4 25 | 1.10× | 2.18× | ||
| Q3 25 | 1.66× | 1.98× | ||
| Q2 25 | 8.87× | 2.14× | ||
| Q1 25 | 2.23× | 3.65× | ||
| Q4 24 | — | 2.12× | ||
| Q3 24 | — | 0.47× | ||
| Q2 24 | — | 1.93× | ||
| Q1 24 | 1.00× | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PAY
| Payment Transaction Processing Revenue | $326.9M | 99% |
| Other | $3.5M | 1% |
